Sign up Australia
Proactive Investors - Run By Investors For Investors

Actinogen Medical enrols first UK patient in Alzheimer’s therapy trial

The annual cost of managing Alzheimer’s disease is estimated to be US$250B in the U.S.
Actinogen Medical enrols first UK patient in Alzheimer’s therapy trial
The patient in UK was enrolled at St. Pancras Clinical Research in London

Actinogen Medical (ASX:ACW) has enrolled its first UK patient into XanADu, its international Phase II efficacy and safety trial of Xanamem therapy in patients with mild Alzheimer’s disease.

Xanamem has been specifically designed to block the excess production of cortisol, the stress hormone, in the areas of the brain most affected by Alzheimer’s disease.

The patient in UK was enrolled at St. Pancras Clinical Research in London. This is the sixteenth patient to be enrolled globally across the eighteen research sites currently open.

Actinogen’s trial will enrol 174 patients at 20 research sites across Australia, the U.S. and the UK.

To-date, over 50 patients have been screened for the study, with at least half expected to progress to enrolment into the trial.

The first XanADu patient will complete the study next month, having reached the end of the 12-week dosing period, and now entering the 4-week follow up phase of the trial.

It is estimated that there are nearly 50 million people with Alzheimer’s disease worldwide, increasing to 131 million by 2050, making it critical to find effective new drugs to treat the disease.

The progress in the development of Xanamem is expected to provide an opportunity for Actinogen to make a profound difference to Alzheimer’s patients and their carers worldwide.

Actinogen ended the June quarter with $3.98 million in cash.





Register here to be notified of future ACW Company articles
View full ACW profile View Profile

Actinogen Medical Ltd Timeline

Newswire
December 30 2016

Related Articles

Regeneus: Access latest PPT from Proactive's CEO Sessions
June 19 2017
John Martin discussed regenerative medicine with investors.
Cancer cells
September 05 2017
In an initiation note on the company, finnCap’s analysts noted that ANGLE is focused on the development of Parsortix, an instrument platform with recurring revenues designed to isolate and harvest rare circulating tumour cells from a patient’s blood sample
newspaper with word cancer magnified
July 11 2017
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use